Literature DB >> 11459078

Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons.

M Hartbauer1, B Hutter-Paie, M Windisch.   

Abstract

Cerebrolysin (Cere, EBEWE Arzneimittel, Austria), a peptidergic drug produced by a standardised enzymatic breakdown of porcine brain proteins, consists of a mixture of 75% free amino acids and 25% low molecular weight peptides (<10 k DA). Cerebrolysin was shown to protect against MAP2 loss in primary embryonic chick neuronal cultures after brief histotoxic hypoxia and in a rat model of acute brain ischemia. Since MAP2 is involved in processes like neuronal growth, plasticity and dendritic branching, we address the question whether Cere is protecting processes against degeneration in a chronic low serum (2% FCS) cell stress model and whether the spontaneous outgrowth of axon-like processes is influenced. This was accomplished by quantification of the neurite lengths of embryonic chicken telencephalon neurons after 4 and 8 days. Additionally, time-lapse video microscopy was performed to study a possible influence of Cere on the growth cone behaviour of axon-like processes. To distinguish between effects caused by the peptide fraction and the effects related to free amino acids, we used an artificial amino acid solution (AA-mix). Results demonstrate a process outgrowth promoting effect of the AA-mix and Cere after 4 DIV. After 8 days neuronal network degeneration occurred in the AA-mix treated cultures, whereas Cere treated cultures still presented a well differentiated neuronal network. Dying neurons could release factors possibly impeding neurite outgrowth and Cere was shown to increase the viability of chicken cortical neurons. Neither the addition of BDNF nor serum supplementation (5% and 10% FCS) could protect the neuronal network against degeneration after 8 DIV, although these treatments were shown to ameliorate the viability of chicken telencephalon neurons. This result together with the finding obtained using the artificial amino acid solution points to the peptide fraction of Cere to be responsible for the protection of processes against degeneration. Time-lapse studies of Cere treated cultures revealed a significant decrease of the velocities characterising random growth cone movements, which is thought to be responsible for an increase in the length of axon-like processes after 4 DIV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459078     DOI: 10.1007/s007020170058

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  11 in total

1.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

2.  Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.

Authors:  E Schauer; R Wronski; J Patockova; H Moessler; E Doppler; B Hutter-Paier; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

3.  Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edith Schreiner; Robert Wronski
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 4.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Authors:  Edith Doppler; Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Anthony Adame; Leslie Crews; Monika Hitzl; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2008-07-04       Impact factor: 17.088

Review 6.  Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

Authors:  Natalia Guzior; Anna Wieckowska; Dawid Panek; Barbara Malawska
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

7.  A multimodal pharmacological agent in combination with recanalization therapy (thrombolysis and thrombectomy) in severe stroke patients.

Authors:  Zdravka Poljakovic; Josip Ljevak; Svjetlana Supe; Katarina Starcevic
Journal:  J Med Life       Date:  2019 Oct-Dec

8.  Cerebrolysin for vascular dementia.

Authors:  Shuhui Cui; Ning Chen; Mi Yang; Jian Guo; Muke Zhou; Cairong Zhu; Li He
Journal:  Cochrane Database Syst Rev       Date:  2019-11-11

9.  Correlates of Post-Stroke Brain Plasticity, Relationship to Pathophysiological Settings and Implications for Human Proof-of-Concept Studies.

Authors:  Eduardo H Sanchez-Mendoza; Dirk Matthias Hermann
Journal:  Front Cell Neurosci       Date:  2016-08-05       Impact factor: 5.505

10.  Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial.

Authors:  K Gharagozli; A A Harandi; S Houshmand; N Akbari; D F Muresanu; J Vester; S Winter; H Moessler
Journal:  J Med Life       Date:  2017 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.